IRadimed

IRMD · NASDAQ

$88.24+$0.59 (+0.67%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $87.65

IRMD analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $120.36 (+36.4% upside)

Low: $117.16
Now: $88.24
High: $126.00

Upgrades and downgrades

The latest rating actions, newest first

IRMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Sep 22, 2026	Initiates	Hold	—	39%
Freedom Broker	Apr 2, 2026	Initiates	Buy	$116.00	45%

The case for and against

Updated Nov 24, 2024

Bull case

iRadimed Corp has demonstrated impressive growth with a 52.2% increase in IV pump sales, amounting to $6.9 million, driven by a substantial rise in unit sales from 122 to approximately 186 pumps. For 2024, projections indicate continued strong performance with expected IV pump sales increasing by 12% to $21.9 million and related disposables sales also rising by 11% to $21.7 million, underpinned by strategic initiatives such as ceasing service on older pump models which is expected to catalyze replacements. Furthermore, the anticipation of a new pump launch in early 2025 and improvements in lead times contribute to a positive outlook, with management forecasting double-digit topline growth rates even in a transitional year.

Bear case

iRadimed Corp is experiencing a decline in revenue growth, dropping from 23% in 2023 to an anticipated lower figure, alongside decreasing operating margins due to infrastructure investments for the upcoming product launch. Sales of the company's monitoring systems decreased by 11% and were below estimates, prompting a more conservative revenue outlook and delaying expectations for the new pump's launch to late 2025. Additionally, potential technical issues with the mRidium pump, along with unexpected competition or regulatory hurdles, could pose significant risks to the company's financial stability, leading to a downward adjustment in revenue projections.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.